FDA approves Itvisma for spinal muscular atrophy
The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in the survival motor neuron ...
23 hours ago
0
0









